Inventor · disambiguated record
Philip Jones
Also filed as: JONES PHILIP · Jones Philip Xinhe
67 granted patents·29 pending applications·404 citations·filing 2005–2025
99Inventor score
Files withUNIV TEXAS57ANGELETTI P IST RICHERCHE BIO9JONES PHILIP6NAVIRE PHARMA INC5BOARD OF REGENTS UNIV OF TEXAS SYSTEM4
Top patents by PatentIndex Score
96 records- 0196US11603365B2Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamideUNIV TEXAS·Filed 2020·Granted Mar 14, 2023·4 cites·30 claims
- 0296US11370786B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2020·Granted Jun 28, 2022·6 cites·17 claims
- 0396US8071623B2Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitorsJONES PHILIP·Filed 2008·Granted Dec 6, 2011·85 cites·9 claims
- 0495US11958849B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2022·Granted Apr 16, 2024·2 cites·12 claims
- 0595US10954243B2Substituted heterocyclic inhibitors of PTPN11NAVIRE PHARMA INC·Filed 2019·Granted Mar 23, 2021·35 cites·18 claims
- 0695US10899740B2Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamideUNIV TEXAS·Filed 2019·Granted Jan 26, 2021·8 cites·15 claims
- 0795US10280171B2Heterocyclic inhibitors of PTPN11UNIV TEXAS·Filed 2017·Granted May 7, 2019·24 cites·37 claims
- 0894US12186324B2Imidazopiperazine inhibitors of transcription activating proteinsUNIV TEXAS·Filed 2021·Granted Jan 7, 2025·3 cites·26 claims
- 0994US10766892B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2019·Granted Sep 8, 2020·9 cites·26 claims
- 1094US10150753B2Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamideUNIV TEXAS·Filed 2016·Granted Dec 11, 2018·7 cites·15 claims
- 1193US11713313B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2020·Granted Aug 1, 2023·3 cites·12 claims
- 1293US9809588B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2015·Granted Nov 7, 2017·15 cites·27 claims
- 1392US10738043B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2018·Granted Aug 11, 2020·6 cites·12 claims
- 1492US10392376B2Heterocyclic inhibitors of ATR kinaseUNIV TEXAS·Filed 2018·Granted Aug 27, 2019·7 cites·32 claims
- 1592US10344025B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2017·Granted Jul 9, 2019·12 cites·11 claims
- 1691US10125128B2GLS1 inhibitors for treating diseaseBOARD OF REGENTS UNIV OF TEXAS SYSTEM·Filed 2016·Granted Nov 13, 2018·13 cites·21 claims
- 1790US8188084B2Pyridinone and pyridazinone derivatives as inhibitors of poly (ADP-ribose) polymerase (PARP)JONES PHILIP·Filed 2007·Granted May 29, 2012·24 cites·2 claims
- 1889US11058688B2Imidazopiperazine inhibitors of transcription activating proteinsUNIV TEXAS·Filed 2019·Granted Jul 13, 2021·3 cites·41 claims
- 1989US10421765B2Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinaseUNIV TEXAS·Filed 2018·Granted Sep 24, 2019·7 cites·39 claims
- 2089US9115120B2Heterocyclic modulators of HIF activity for treatment of diseaseUNIV TEXAS·Filed 2013·Granted Aug 25, 2015·9 cites·9 claims
- 2188US9663504B2Salts of heterocyclic modulators of HIF activity for treatment of diseaseBOARD OF REGENTS UNIV OF TEXAS SYSTEM·Filed 2015·Granted May 30, 2017·6 cites·30 claims
- 2288US7834015B2Pyrrolo[1,2-a] pyrazin-1(2H)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP)ANGELETTI P IST RICHERCHE BIO·Filed 2007·Granted Nov 16, 2010·20 cites·8 claims
- 2387US11104675B2PTPN11 inhibitorsNAVIRE PHARMA INC·Filed 2019·Granted Aug 31, 2021·6 cites·24 claims
- 2486US11400108B2Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signallingUNIV TEXAS·Filed 2020·Granted Aug 2, 2022·1 cites·24 claims
- 2586US10933078B2Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signallingUNIV TEXAS·Filed 2018·Granted Mar 2, 2021·2 cites·28 claims
- 2686US10800769B2Heterocyclic inhibitors of ATR kinaseUNIV TEXAS·Filed 2019·Granted Oct 13, 2020·2 cites·16 claims
- 2786US10562916B2Substituted quinoxalines as PDE-10 inhibitorsSUNOVION PHARMACEUTICALS INC·Filed 2017·Granted Feb 18, 2020·4 cites·24 claims
- 2886US2024360121A1Gls1 inhibitors for treating diseaseUNIV TEXAS·Filed 2024·Application pending·0 cites
- 2985US10899769B2Imidazopiperazinone inhibitors of transcription activating proteinsUNIV TEXAS·Filed 2019·Granted Jan 26, 2021·3 cites·26 claims
- 3085US10093664B2Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of diseaseUNIV TEXAS·Filed 2017·Granted Oct 9, 2018·4 cites·24 claims
- 3185US7799825B2Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitorsANGELETTI P IST RICHERCHE BIO·Filed 2007·Granted Sep 21, 2010·9 cites·10 claims
- 3285US2025041324A1Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signallingUNIV TEXAS·Filed 2024·Application pending·0 cites
- 3384US12252480B2Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamideUNIV TEXAS·Filed 2023·Granted Mar 18, 2025·0 cites·10 claims
- 3484US10851110B2Heterocyclic inhibitors of PTPN11UNIV TEXAS·Filed 2019·Granted Dec 1, 2020·4 cites·20 claims
- 3584US10745420B2Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinaseUNIV TEXAS·Filed 2019·Granted Aug 18, 2020·2 cites·26 claims
- 3683US11560366B2Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of diseaseUNIV TEXAS·Filed 2020·Granted Jan 24, 2023·1 cites·24 claims
- 3783US9481692B2Heterocyclic modulators of HIF activity for treatment of diseaseBOARD OF REGENTS UNIV OF TEXAS SYSTEM·Filed 2015·Granted Nov 1, 2016·4 cites·10 claims
- 3883US8268827B2Pyridazinone derivatives as PARP inhibitorsBRANCA DANILA·Filed 2008·Granted Sep 18, 2012·13 cites·12 claims
- 3983US7977374B2Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitorsANGELETTI P IST RICHERCHE BIO·Filed 2006·Granted Jul 12, 2011·8 cites·6 claims
- 4082US10208059B2Heterocyclic modulators of HIF activity for treatment of diseaseBOARD OF REGENTS UNIV OF TEXAS SYSTEM·Filed 2016·Granted Feb 19, 2019·3 cites·6 claims
- 4181US10363248B2Salts of heterocyclic modulators of HIF activity for treatment of diseaseUNIV TEXAS·Filed 2017·Granted Jul 30, 2019·2 cites·28 claims
- 4280US12036231B2Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signallingUNIV TEXAS·Filed 2022·Granted Jul 16, 2024·0 cites·20 claims
- 4380US11001594B2Heterocyclic modulators of HIF activity for treatment of diseaseUNIV TEXAS·Filed 2018·Granted May 11, 2021·1 cites·12 claims
- 4480US9018380B2Heterocyclic modulators of HIF activity for treatment of diseaseINST APPLIED CANCER SCIENCE THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CT·Filed 2013·Granted Apr 28, 2015·7 cites·10 claims
- 4580US2025127792A1Imidazopiperazine inhibitors of transcription activating proteinsUNIV TEXAS·Filed 2024·Application pending·0 cites
- 4680US2025188074A1Ptpn11 inhibitorsNAVIRE PHARMA INC·Filed 2024·Application pending·0 cites
- 4778US8765760B2[1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterasesCAMPBELL JOHN EMMERSON·Filed 2012·Granted Jul 1, 2014·3 cites·22 claims
- 4878US7863294B2Heterocycle derivatives as histone deacetylase (HDAC) inhibitorsANGELETTI P IST RICHERCHE BIO·Filed 2005·Granted Jan 4, 2011·5 cites·18 claims
- 4977US11028083B2Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferasesUNIV TEXAS·Filed 2019·Granted Jun 8, 2021·1 cites·36 claims
- 5076US10800774B2Heterocyclic inhibitors of ATR kinaseUNIV TEXAS·Filed 2018·Granted Oct 13, 2020·2 cites·25 claims
Showing the top 50 of 96 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Philip Jones files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →